We are live on ! Find out more

Mirum Pharmaceuticals

MIRM

Market cap $6.28B

96.75 USD

-1.47

1.5%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

96.75

0.00

0%

1 day

-1.5%

5 days

-1.77%

1 month

-3.87%

3 months

-4.21%

6 months

4.44%

Year to date

23.93%

1 year

30.41%

5 years

442.93%

10 years

632.4%

About: Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Employees: 433

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 52.4%

Negative 4.8%

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer.

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

Zacks Investment Research

Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

Investors Business Daily

Insmed Catapults 30%, Leading A Biotech Rally; But Mirum Takes A Bath

Insmed stock led a biotech rally Thursday, catapulting 30% on solid second-quarter sales for its new lung disease drug, Brinsupri.

Insmed Catapults 30%, Leading A Biotech Rally; But Mirum Takes A Bath

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript

Mirum Pharmaceuticals Q2 Earnings Call Highlights

Mirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.

Mirum Pharmaceuticals Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™